Voyager Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $151.6M
- Price
- $2.46
- % Change (Daily % change from the live per-ticker quote feed.)
- 0.00%
- Volume
- 290.9K
About
Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. Additionally, Voyager is pursuing a Tau program aimed at various tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, alongside initiatives for spinal muscular atrophy. To advance its gene therapy product pipeline, the company has forged strategic collaboration and licensing agreements with key industry players such as Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. These partnerships cover the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and maintains its corporate headquarters in Cambridge, Massachusetts.
Quick stats
Shares outstanding61.6M
Computed float46.9M
Float / shares76.1%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001640266
AI Summary
AI-generated1/15
minorneutralother
Voyager to Present at Upcoming Investor Conferences
Voyager Therapeutics announced its participation in five upcoming investor conferences, including events hosted by Wells Fargo, Morgan Stanley, and Baird. The fireside chats are scheduled between September 8 and September 15 in Boston and New York.
A webcast of the Wells Fargo session will be accessible via the company's website, with a replay available for 30 days.
Voyager is a biotechnology company developing genetic medicines for neurological diseases like Alzheimer's and Parkinson's, utilizing its TRACER platform. The company advances programs both independently and with partners such as Alexion, Novartis, and Neurocrine.